Literature DB >> 3549914

Receptor-mediated clearance of Aspergillus galactomannan.

J E Bennett, M M Friedman, B Dupont.   

Abstract

The fate of radiolabeled Aspergillus fumigatus galactomannan was studied after intravenous injection into rabbits and rats. At 1 hr, the liver contained 35% of the injected dose in rabbits and 30% in rats. Excretion of galactomannan into the urine, measured in rabbits, was another major catabolic route and accounted for 35% of the dose by 24 hr. Immunization of rabbits increased hepatic uptake and decreased urinary excretion. Hepatic uptake in unimmunized rats could be decreased by Saccharomyces cerevisiae mannan, alpha-methyl mannoside, and N-acetylglucosamine, known inhibitors of the macrophage mannose receptor. Autoradiography showed hepatic radiolabeled galactomannan to be concentrated in Kupffer cells, which express the mannosyl receptor for glycoproteins. Macrophage mannosyl receptors may constitute a general mechanism for clearing fungal mannans from the bloodstream.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549914     DOI: 10.1093/infdis/155.5.1005

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients.

Authors:  Eun Jeong Kwak; Shahid Husain; Asia Obman; Lisa Meinke; Janet Stout; Shimon Kusne; Marilyn M Wagener; Nina Singh
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments.

Authors:  Emmanuelle Bart-Delabesse; Maria Basile; Ahmad Al Jijakli; Didier Souville; Frédérick Gay; Bruno Philippe; Philippe Bossi; Martin Danis; Jean-Paul Vernant; Annick Datry
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Production and characterization of monoclonal antibodies to cell wall antigens of Aspergillus fumigatus.

Authors:  L Ste-Marie; S Sénéchal; M Boushira; S Garzon; H Strykowski; L Pedneault; L de Repentigny
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

5.  Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis.

Authors:  Wei Zhou; Hongxing Li; Yan Zhang; Mei Huang; Qian He; Pei Li; Fang Zhang; Yi Shi; Xin Su
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

Review 6.  Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.

Authors:  Laura L Kovanda; Amit V Desai; William W Hope
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-08       Impact factor: 2.745

Review 7.  Serological techniques for diagnosis of fungal infection.

Authors:  L de Repentigny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

8.  Aspergillus Fumigatus antigen detection in sera from patients at risk for invasive aspergillosis.

Authors:  B F Chumpitazi; C Pinel; B Lebeau; P Ambroise-Thomas; R Grillot
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

9.  Discordant rise in galactomannan antigenemia in a patient with resolving Aspergillosis, renal failure, and ongoing hemodialysis.

Authors:  Chadi M El Saleeby; Kim J Allison; Katherine M Knapp; Thomas J Walsh; Randall T Hayden
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

10.  Aspergillus antigenuria compared to antigenemia in bone marrow transplant recipients.

Authors:  R Ansorg; E Heintschel von Heinegg; P M Rath
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.